Targeted therapies in optic pathway gliomas
Targeted therapies constitute a potentially paradigm-shifting development in the management of OPGs, enhancing disease control while improving the prospects for long-term visual preservation. This review underscores the need for individualized, biomarker-driven approaches and highlights challenges including resistance, long-term safety, and therapy duration.
Authors
- Luca Denaro (ORCID: https://orcid.org/0000-0002-2529-6149)
- Amedeo Piazza (ORCID: https://orcid.org/0000-0001-5360-5810)
- Marta Padovan (ORCID: https://orcid.org/0000-0001-7362-3127)
- Daniele Tognetto (ORCID: https://orcid.org/0000-0001-7197-7765)
- Marco Zeppieri (ORCID: https://orcid.org/0000-0003-0999-5545)
- Matthias Preusser (ORCID: https://orcid.org/0000-0003-3541-2315)
- Caterina Gagliano (ORCID: https://orcid.org/0000-0001-8424-0068)
- E. Agosti
- Giorgia De Rosa
- Giuseppe Lombardi
- Tamara Ius
- Marco Maria Fontanella
- Pier Paolo Panciani
- Karen Mapelli (ORCID: https://orcid.org/0009-0001-5957-8689)
Institutions
- University of Udine (IT)
- University of Padua (IT)
- University of Trieste (IT)
- Università degli Studi di Enna Kore (IT)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- Istituto Oncologico Veneto (IT)
- Ospedale Santa Maria della Misericordia di Udine (IT)
- Medical University of Vienna (AT)
- University of Brescia (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Cancer Treatment Reviews
- Published
- 2025-12-27
- DOI
- https://doi.org/10.1016/j.ctrv.2025.103073
- Primary Topic
- Neurofibromatosis and Schwannoma Cases
- Type
- article
- Field-Weighted Citation Impact
- 0.00